Background GMZ2 is a recombinant malaria vaccine inducing immune responses against
Plasmodium falciparum (Pf) merozoite surface protein-3 and glutamate-rich protein. We …

Background. GMZ2 is a hybrid protein consisting of the N-terminal region of the glutamate-
rich protein fused in frame to the C-terminal region of merozoite surface protein 3 (MSP3) …

Malaria is still one of the major public health threats in sub-Saharan Africa. An effective
vaccine could be a sustainable control measure that can be integrated into existing health …

Introduction: GMZ2 is a recombinant protein consisting of conserved domains of GLURP and
MSP3, two asexual blood-stage antigens of Plasmodium falciparum, and is designed with …

Background GMZ2 is a fusion protein of Plasmodium falciparum merozoite surface protein 3
(MSP3) and glutamate rich protein (GLURP) that mediates an immune response against the …

Background GMZ2 is a recombinant protein malaria vaccine, comprising two blood-stage
antigens of Plasmodium falciparum, glutamate-rich protein and merozoite surface protein 3 …

Malaria is a major public health problem in Sub-Saharan Africa. In highly endemic regions
infants, children and pregnant women are mostly affected. An effective malaria vaccine …

Background Helminths can modulate the host immune response to Plasmodium falciparum
and can therefore affect the risk of clinical malaria. We assessed here the effect of helminth …

Immunization with radiation-attenuated Plasmodium falciparum (Pf) sporozoites (SPZ) in
PfSPZ Vaccine, has provided better vaccine efficacy (VE) against controlled human malaria …

GMZ2 is a malaria vaccine candidate evaluated in a phase 2b multi-centre trial. Here we
assessed antibody responses and the association of naturally acquired immunity with …